Apr 5 |
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
|
Apr 4 |
New Strong Sell Stocks for April 4th
|
Apr 3 |
Immunome files to sell 2.18M common shares for holders
|
Apr 2 |
Immunome: An Oncology Powerhouse In The Making
|
Mar 28 |
Immunome GAAP EPS of -$5.38
|
Mar 28 |
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
|
Mar 26 |
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
|
Mar 26 |
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
|
Mar 22 |
Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions
|
Mar 7 |
Immunome to Participate in the Leerink Partners Global Biopharma Conference
|